Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

LITFULO

Drug and asset intelligence for LITFULO with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 1
Stage: Development stage unavailable

Sponsor company

Mechanism of action

JAK Inhibitor

Recent signals(2)

ClinicalJuly 31, 2026

Pfizer Reports Positive Phase 3 Results for LITFULO in Nonsegmental Vitiligo

LITFULO (ritlecitinib) demonstrated significant improvement in facial and total repigmentation in patients with nonsegmental vitiligo in two Phase 3 trials.

RegulatoryJuly 8, 2026

FDA Approves Supplemental NDA for Pfizer's Ritlecitinib Tosylate (Litfulo)

The FDA has approved a supplemental NDA for Litfulo (ritlecitinib tosylate) submitted by Pfizer.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

(1)

Topline Data

Pfizer — Litfulo

July 8, 2026 · N/A

Indications

Autoimmune Disease →

Therapeutic areas

Autoimmune Disease →

Dermatology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.